Peggy Scherle
2021
In 2021, Peggy Scherle earned a total compensation of $2.6M as Chief Scientific Officer at Prelude Therapeutics, a 2% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $156,000 |
|---|---|
| Option Awards | $2,068,828 |
| Salary | $408,271 |
| Total | $2,633,099 |
Scherle received $2.1M in option awards, accounting for 79% of the total pay in 2021.
Scherle also received $156K in non-equity incentive plan and $408.3K in salary.
Rankings
In 2021, Peggy Scherle's compensation ranked 4,949th out of 12,415 executives tracked by ExecPay. In other words, Scherle earned more than 60.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,949 out of 12,415 | 60th |
Division Manufacturing | 2,076 out of 5,505 | 62nd |
Major group Chemicals And Allied Products | 884 out of 2,375 | 63rd |
Industry group Drugs | 791 out of 2,096 | 62nd |
Industry Pharmaceutical Preparations | 563 out of 1,546 | 64th |
Source: SEC filing on April 29, 2022.
Scherle's colleagues
We found three more compensation records of executives who worked with Peggy Scherle at Prelude Therapeutics in 2021.